Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRT1419 in Relapsed/Refractory Hematologic Malignancies
NCT04543305Phase 1Completed
- Sponsor
- Prelude Therapeutics
- Start
- Sep 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PRT1419 in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), myelodysplastic syndromes (MDS) and 3 more (2 arms), sponsored by Prelude Therapeutics. Primary endpoints: Dose Limiting Toxicities at Day 28, Maximally Tolerated Dose at 2 years and 1 more. Started Sep 2020; status: completed.
02
Drugs
PRT1419
03
Conditions
acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)myelodysplastic syndromes (MDS)Myelodysplastic/myeloproliferative neoplasm overlap syndrome (MDS/MPN)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04543305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04543305.